Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317059 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MMP2MEN1KMT2ALMNA | |
| SCHEMBL240405 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MMP2MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL4371678 | 0.98 | ALDH1A1 (0.64) | ALDH1A1MMP2MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL1230535 | 0.98 | ALDH1A1 (0.64) | ALDH1A1MMP2MEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL240404 | 0.98 | ALDH1A1 (0.64) | ALDH1A1MMP2MEN1KMT2ALMNA | |
| SCHEMBL27546222 | 0.98 | ALDH1A1 (0.61) | ALDH1A1MMP2MEN1KMT2ALMNA | |
| SCHEMBL8211198 | 0.93 | ALDH1A1 (0.56) | ALDH1A1MMP2MEN1KMT2ADPP4 | |
| SCHEMBL4097192 | 0.93 | ALDH1A1 (0.56) | ALDH1A1MMP2MEN1KMT2ADPP4 | |
| SCHEMBL11651148 | 0.88 | MMP2 (0.49) | ALDH1A1MMP2LMNADPP4DPP7 | |
| SCHEMBL1859542 | 0.87 | MAPT (0.50) | ALDH1A1MMP2LMNADPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
| CN-109104863-A | Somatostatin receptor antagonist compound and its application method | 克德瑞德风险投资公司 | 2018-12-28 | — | — | CN | disclosed |
| EP-3414259-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD Ventures Inc. (CA) | 2018-12-19 | — | — | EP | disclosed |
| WO-2007028639-A1 | METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF | THERAPHARM GMBH (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-6235876-B1 | Liquid phase process for the preparation of GNRH peptides | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-05-22 | — | — | US | disclosed |
| US-5977075-A | N-aroylamino acid amides as endothelin inhibitors | NOVARTIS AG (CH) | 1999-11-02 | — | — | US | disclosed |
| US-5977302-A | SOLUTION PHASE SYNTHESIS PERMITTING LARGE SCALE BULK PRODUCTION USING A MINIMUM NUMBER OF STEPS; REDUCED UNWANTED SIDE REACTIONS AND ELIMINATION OF SIDE CHAIN PROTECTION STEPS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999026964-A1 | LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5780498-A | PEPTIDE DERIVATIVES FOR CARDIOVASCULAR AND BRAIN DISORDERS | CIBA-GEIGY JAPAN LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0821670-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | Novartis AG (CH) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | disclosed |
| EP-0728145-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | Ciba-Geigy Japan Limited (JP) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995012611-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | JAPAT LTD. (CH) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | ALDH1A1 4110/4885MMP2 3213/4885MEN1 203/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | ALDH1A1 4077/4885MMP2 3203/4885MEN1 205/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | ALDH1A1 4110/4885MMP2 3213/4885MEN1 203/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | ALDH1A1 4077/4885MMP2 3203/4885MEN1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.